Mitoxantrone

• UNSPSC Description:

  Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity[1][2][3][4]. Mitoxantrone also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively[5].

• Target Antigen:

  Apoptosis; Endogenous Metabolite; Orthopoxvirus; PKC; Topoisomerase

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Apoptosis;Cell Cycle/DNA Damage;Epigenetics;Metabolic Enzyme/Protease;TGF-beta/Smad

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/mitoxantrone.html

• Smiles:

  O=C1C2=C(C(NCCNCCO)=CC=C2NCCNCCO)C(C3=C(O)C=CC(O)=C13)=O

• Molecular Weight:

  444.48

• References & Citations:

  [1]Takeuchi N, et al. Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J Biochem. 1992 Dec;112(6):762-7.|[2]Bellosillo B, et al. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.|[3]Vibet S, et al. Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines. Drug Metab Dispos. 2007 May;35(5):822-8.|[4]Fujimoto S, et al. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Cancer Chemother Pharmacol. 1982;8(2):157-62.|[5]Sharon E Altmann, et al. Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone. Antiviral Res. 2012 Feb;93(2):305-308. Acta Pharmacol Sin. 2022 Aug 31.|Acta Pharmacol Sin. 2024 Aug 15.|Adv Mater. 2024 Apr 21:e2313097.|bioRxiv. 2024 September 07.|Cancers. 2020 Aug 4;12(8):2169.|Cell Rep Med. 2024 Feb 20;5(2):101388.|EMBO Mol Med. 2024 Oct 11.|Exp Cell Res. 2020 Aug 1;393(1):112054.|Int J Biol Sci. 2022 Mar 21;18(6):2568-2582.|J Am Chem Soc. 2022 Jun 15;144(23):10407-10416.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|J Pharm Pharmacol. 2022 Jan 5;74(1):41-56.|J Pharm Pharmacol. 23 November 2021.|Light Sci Appl. 2024 Oct 31;13(1):304.|Mol Cell. 2024 Jun 18:S1097-2765(24)00447-7.|Nat Cell Biol. 2024 May 7.|Patent. US20240307414A1.|Pharm Dev Technol. 2021 Apr 30;1-9.|Pharmacol Res. 2024 May 9:204:107208.|Research Square Print. November 28th, 2022.|Talanta. 2024 Mar 23, 125987.|University of California, Irvine. 2024.|bioRxiv. 2023 Jan 13.|BMC Cancer. 2021 Oct 13;21(1):1101.|Cell Oncol. 2020 Dec;43(6):1099-1116.|Cell Rep Methods. 2023 Oct 23;3(10):100599.|Drug Deliv. 2022 Dec;29(1):2561-2578.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|Med Oncol. 2020 Nov 19;37(12):116.|Nat Commun. 2020 Apr 14;11(1):1792.

• Shipping Conditions:

  Blue Ice

• CAS Number:

  65271-80-9